comparemela.com

Latest Breaking News On - Nordic issuing - Page 1 : comparemela.com

Episurf Medical AB: Episurf Medical publishes prospectus in connection with the company s partially guaranteed rights issue of up to approximately SEK 120 million

Episurf Medical AB: Episurf Medical publishes prospectus in connection with the company s partially guaranteed rights issue of up to approximately SEK 120 million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Curasight publishes information memorandum in connection with forthcoming rights issue

Curasight publishes information memorandum in connection with forthcoming rights issue
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Curasight resolves on a rights issue of up to DKK 51 2 million to accelerate its therapeutic strategy

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/  Curasight A/S Curasight or the Company – has today resolved on a new issue of shares with preferential rights for the Company s existing.

Toleranzia AB: Toleranzia carries out a rights issue of units of approximately SEK 55 million

Toleranzia AB: Toleranzia carries out a rights issue of units of approximately SEK 55 million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Cline Scientific: Cline Scientific AB publishes memorandum regarding the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIB.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.